This is a synthetic peptide designed for use in combination with anti-NFKBIB antibody (Catalog #: ARP34505_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
NFKBIB
Reaktivität: Human
Wirt: Synthetic
BP, WB, IHC
Applikationshinweise
Each Investigator should determine their own optimal working dilution for specific applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Konzentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
NFKBIB
(NF-kappa-B inhibitor beta (NFKBIB))
Hintergrund
Inhibition of NFkappa-B activity by the hepatitis C virus core protein might be related to its physical interaction with and interrupted nuclear localization of IKKbeta. Increased nuclear factor-kappaB (NF-kB) activity in the amnion during labor is associated with an increase in the expression of NF-kBp65 and of the NF-kB binding proteins IkBa, IkBb-1 and IkBb-2. IkappaBbeta may be a novel target for transcription factors of the HMG-box SRY/Sox family and imply a potential role for NF-kappaB/IkappaBbeta in spermatogenesis.
Alias Symbols: IKBB, TRIP9
Protein Interaction Partner: IKBKB,MCC,RELA,RELA,BTRC,CD3EAP,CHUK,CUL1,IKBKB,IKBKG,KPNA2,LRPPRC,MCC,MTIF2,NFKB1,NFKB2,NFKBIA,NGFR,NKIRAS1,NKIRAS2,PDCD2,POLR1A,POLR1B,POLR1C,POLR1D,POLR1E,POLR2H,POLR2L,RASAL2,REL,RELA,RXRA,SKP1,BTRC,CHUK,IKBKB,NKIRAS1,REL,RELA,RXRA,Thrb